Last reviewed · How we verify
Buspirone Hydrochloride 10 MG
At a glance
| Generic name | Buspirone Hydrochloride 10 MG |
|---|---|
| Also known as | Buspiron |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal (NA)
- Buspirone for Weak or Absent Esophageal Peristalsis (PHASE4)
- Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD (PHASE3)
- Buspirone for Early Satiety and Symptoms of Gastroparesis (PHASE2)
- Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial (PHASE1, PHASE2)
- Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia (PHASE1)
- Buspirone for Functional Dysphagia (NA)
- Buspirone, Stress, and Attentional Bias to Marijuana Cues (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buspirone Hydrochloride 10 MG CI brief — competitive landscape report
- Buspirone Hydrochloride 10 MG updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI